SCHEMBL1689727

SCHEMBL1689727

CCOC(=O)C=Cc1ccc(C(F)(F)F)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.67
CA1 P00915 1/20 0.67
CA2 P00918 1/20 0.67
CA7 P43166 1/20 0.67
CA9 Q16790 1/20 0.67
CA14 Q9ULX7 1/20 0.67
CYP1A2 P05177 1/20 0.60
CYP1A1 P04798 4/20 0.59
CYP1B1 Q16678 4/20 0.59
MAOB P27338 4/20 0.59
CYP3A4 P08684 1/20 0.58
TTR P02766 1/20 0.57
DPP4 P27487 1/20 0.57
HDAC3 O15379 1/20 0.55
ADAM17 P78536 1/20 0.55
HDAC1 Q13547 1/20 0.55
HDAC2 Q92769 1/20 0.55
HDAC10 Q969S8 1/20 0.55
HDAC11 Q96DB2 1/20 0.55
HDAC8 Q9BY41 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1689725 1.00 CA12 (0.67) CA12CA1CA2CA7CA9
SCHEMBL27767011 0.90 CA12 (0.54) CA12CA1CA2CA7CA9
SCHEMBL27485417 0.87 CYP1A1 (0.53) CA12CA1CA2CA7CA9
SCHEMBL10939791 0.87 CA12 (0.86) CA12CA1CA2CA7CA9
SCHEMBL13957401 0.87 CA12 (0.86) CA12CA1CA2CA7CA9
SCHEMBL5059085 0.87 CA12 (0.86) CA12CA1CA2CA7CA9
SCHEMBL6219878 0.86 CA12 (0.51) CA12CA1CA2CA7CA9
SCHEMBL6219883 0.86 CA12 (0.51) CA12CA1CA2CA7CA9
SCHEMBL6219887 0.86 CA12 (0.51) CA12CA1CA2CA7CA9
SCHEMBL4890740 0.86 CA12 (0.69) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119823161-A Synthesis and application of beta-borate-beta-chloro ester compound 陇东学院 2025-04-15 CN disclosed
US-9686990-B2 Spiroindolinepiperidine derivatives SYNGENTA PARTICIPATIONS AG (CH) 2017-06-27 US disclosed
US-20160007608-A1 SPIROINDOLINEPIPERIDINE DERIVATIVES SYNGENTA LIMITED (GB) 2016-01-14 US disclosed
US-9174987-B2 Spiroindolinepiperidine derivatives SYNGENTA LIMITED (DE) 2015-11-03 US disclosed
EP-1880996-B1 SPIROINDOLINEPIPERIDINE DERIVATIVES SYNGENTA LTD (GB) 2014-12-24 EP disclosed
US-20120010220-A1 SPIROINDOLINEPIPERIDINE DERIVATIVES SYNGENTA CROP PROTECTION LLC (US) 2012-01-12 US disclosed
EP-1515969-B1 SPIROINDOLINEPIPERIDINE DERIVATIVES SYNGENTA LTD (GB) 2010-08-25 EP disclosed
EP-1880996-A1 Spiroindolinepiperidine derivatives Syngenta Limited (GB) 2008-01-23 EP disclosed
US-20060106045-A1 Spiroindolinepiperidine derivatives SYNGENTA PARTICIPATIONS AG (CH) 2006-05-18 US disclosed
US-6306880-B1 HETEROCYCLIC ALCOHOL DERIVATIVES AS FUNGICIDES SANKYO COMPANY, LIMITED (JP) 2001-10-23 US disclosed
US-5977152-A Triazole antifungal agent SANKYO COMPANY, LIMITED (JP) 1999-11-02 US disclosed
EP-0885891-A1 ISOXAZOLE DERIVATIVES SANKYO COMPANY LIMITED (JP) 1998-12-23 EP disclosed
EP-0841327-A1 TRIAZOLE ANTIFUNGAL AGENT SANKYO COMPANY LIMITED (JP) 1998-05-13 EP disclosed
EP-0801071-A1 LEWIS X DERIVATIVE AND PROCESS FOR PRODUCING THE SAME SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1997-10-15 EP disclosed
EP-0164852-B1 1-(SUBSTITUTED-ARYL)-DIHYDRO-1H-PYRROLIZINE-3,5-(2H,6H-)DIONES, A PROCESS FOR PRODUCING THE COMPOUNDS AND A PHARMACEUTICAL COMPOSITION COMPRISING THE COMPOUNDS WARNER-LAMBERT COMPANY (US) 1988-07-06 EP disclosed
EP-0164853-B1 (SUBSTITUTED-PHENYL)-5-OXO-2-PYRROLIDINEPROPANOIC ACIDS, A PROCESS FOR PRODUCING THE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS WARNER-LAMBERT COMPANY (US) 1988-07-06 EP disclosed
US-4584313-A TREATING SENILITY WARNER-LAMBERT COMPANY (US) 1986-04-22 US disclosed
EP-0164853-A1 (substituted-phenyl)-5-oxo-2-pyrrolidinepropanoic acids, a process for producing the compounds and pharmaceutical compositions comprising the compounds WARNER-LAMBERT COMPANY (US) 1985-12-18 EP disclosed
EP-0164852-A1 1-(Substituted-aryl)-Dihydro-1H-pyrrolizine-3,5-(2H,6H-)diones, a process for producing the compounds and a pharmaceutical composition comprising the compounds WARNER-LAMBERT COMPANY (US) 1985-12-18 EP disclosed
US-4548947-A 1-(Substituted-aryl)-dihydro-1H-pyrrolizine-3,5-[2H,6H-]diones and use for reversing amnesia WARNER-LAMBERT COMPANY (US) 1985-10-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010220-A1 SPIROINDOLINEPIPERIDINE DERIVATIVES RECQL, OPRD1, SKP1 CA12 4836/4885CA1 4561/4885CA2 2512/4885
US-20060106045-A1 Spiroindolinepiperidine derivatives RECQL, OPRD1, NCAPD3 CA12 4772/4885CA1 4375/4885CA2 2057/4885
US-20160007608-A1 SPIROINDOLINEPIPERIDINE DERIVATIVES RECQL, OPRD1, SKP1 CA12 4836/4885CA1 4561/4885CA2 2512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.